A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Latest Information Update: 19 Jan 2023
Price :
$35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Biomarker; Therapeutic Use
- 13 Dec 2022 Results assessing long-term outcomes and correlated chronic lymphocytic leukemia cell birth and death rates with depth of response over time, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 15 Aug 2018 Status changed from active, no longer recruiting to completed.
- 05 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.